Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations.

Abstract

The treatment for chronic myeloid leukemia has changed significantly over the past 15 years, and as of now, there are five BCR-ABL1 (breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1) tyrosine kinase inhibitors that have gained approval for treatment of this disease. All five are very effective drugs, and the decision surrounding which to use in specific patients is based on numerous factors. Bosutinib is one of the newer tyrosine kinase inhibitors to gain approval, and has been studied in the first-line setting as well as after failure of other tyrosine kinase inhibitors. It is an SRC-ABL1 (steroid receptor co-activator-ABL1) inhibitor that works in the presence of most kinase domain mutations. The primary side effects of bosutinib are gastrointestinal upsets. In the appropriate clinical setting, bosutinib can be considered a valuable addition to the armamentarium of treatments available for chronic myeloid leukemia.

• Authors: Kendra Sweet, Javier Pinilla-Ibarz, Ling Zhang
• Journal: Patient preference and adherence (Patient Prefer Adherence) Vol. 8 Pg. 981-6 ( 2014) ISSN: 1177-889X [Print] New Zealand
• PMID: 25045255 (Publication Type: Journal Article, Review)